This CPB has been revised to state that (i) leuprolide for the treatment of dysmenorrhea that is refractory to oral contraceptives is considered medically necessary, and (ii) leuprolide for the treatment of salivary gland cancer; goserelin for the treatment of chronic pelvic pain and pancreatic cancer are considered experimental and investigational.